AFFILIATIONS
1 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
2 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
3 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 Department of hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
6 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
7 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
8 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
9 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
10 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 Department of hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
12 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
13 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
15 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
ABSTRACT
Background: Genomic loss of the recipient-specific mismatched HLA haplotype is an important immune-escape mechanism of relapse after haploidentical hematopoietic cell transplantation (haplo-HCT). The immunogenetic factors that predispose leukemia to this form of immune escapes remain poorly understood. HLA evolutionary divergence (HED) quantifies amino acid sequence divergence between the peptide-binding regions of HLA alleles and is commonly used as a surrogate for the diversity of immunopeptidome potentially presented by the HLA genotype. We hypothesized that greater divergence between the recipient-specific mismatched HLA allele may be associated with stronger alloimmune selection pressure and preferential emergence of HLA-loss clones.
Methods: We retrospectively analyzed 390 patients with hematologic relapse after haplo-HCT across five centers. HLA loss was assessed by qPCR or next-generation sequencing. HED was calculated using Grantham distance. At each locus, HEDMM represented the distance between the donor-specific and recipient-specific mismatched alleles. HEDD->R was the geometric mean of recipient HED (HEDR) and HEDMM: HEDD->R =sqrt (HEDR×HEDMM). Factors associated with HLA-loss relapse were evaluated using multivariable logistic regression. Post-relapse survival was measured from relapse.
Results: Among 390 relapsed patients, 154 (39.5%) were HLA-loss and 236 were HLA-retained relapse. Patients with HLA-loss relapse had higher HEDD->R at HLA-A (median, 7.51 vs 5.02; P=0.004) and HLA-DRB1 (11.97 vs 10.01; P=0.002), as well as higher HED_MM at HLA-A (8.71 vs 7.94; P=0.025). In multivariable analyses, each 3-unit increase in HEDD->R at HLA-DRB1 was associated with higher odds of HLA-loss relapse in the overall (OR, 1.26; 95% CI, 1.05–1.52), myeloid (OR, 1.29; 95% CI, 1.07–1.54), and lymphoid cohorts (OR, 1.42; 95% CI, 1.06–1.90). Other immunogenetic features, including the number of HLA mismatches, KIR-ligand and HLA-B leader status, were not significantly associated with the HLA loss phenotype.
Prophylactic donor lymphocyte infusion (DLI) before relapse was independently associated with higher odds of HLA loss rather than HLA-retained phenotype at relapse in the overall (OR 4.41, 95% CI 2.46-7.91), myeloid (OR 3.77, 95% CI 1.85-7.66), and lymphoid cohorts (OR 6.17, 95% CI 2.10-18.14). Additionally, II-IV aGVHD (OR 2.58,95%CI 1.26-5.28) before relapse and a longer interval from HCT to relapse (OR per 6-month increase, 1.37; 95%CI 1.18-1.60) were also independently associated with higher odds of HLA loss at relapse in myeloid cohort.
Post-relapse survival did not differ significantly between the HLA-loss and HLA-retained groups. In the myeloid cohort, among patients with HLA-retained relapse, chemotherapy combined with therapeutic DLI (HR, 0.679; 95% CI, 0.465–0.991) and second HCT (HR, 0.421; 95% CI, 0.216–0.820) were associated with improved survival, whereas second HCT was the only factor independently associated with improved survival (HR, 0.383; 95% CI, 0.204–0.718) for patients with HLA- loss relapse. In B-ALL, blinatumomab was associated with longer survival in both HLA-retained (HR, 0.30; 95% CI, 0.11–0.81) and HLA-loss relapse (HR, 0.23; 95% CI, 0.08–0.59).
Conclusion: Susceptibility to HLA-loss phenotype at relapse may be partly determined by a pre-existing, locus-specific pattern of donor–recipient HLA evolutionary divergence. Locus-specific HED might be a candidate biomarker of immune-escape phenotype and warrant validation in larger haplo-HCT cohorts.
DISCLOSURES
Ruowen Wei, PhD: No relevant conflicts of interest to declare.